key: cord-0828420-si8nzwgl
authors: Blanc, Kim; Bonnet, Nicolas; Ouedraogo, Elise; Arnaout, Michel; Patout, Maxime; Tandjaoui-Lambiotte, Yacine
title: Interstitial lung disease-related pneumomediastinum in COVID-19 patients
date: 2021-03-08
journal: ERJ Open Res
DOI: 10.1183/23120541.00014-2021
sha: 39149c5dffbb15702aaaacfb6ef3f396f83e2b4e
doc_id: 828420
cord_uid: si8nzwgl

Pneumomediastinum in severe #COVID19 presentations could be due to a lung parenchymal retractive process generated by intense inflammation as in acute exacerbation of idiopathic pulmonary fibrosis or MDA-5 acute interstitial lung disease https://bit.ly/3qzBYMW

To the Editor:

We read with interest the work of LEMMERS et al. [1] published recently in this journal. We also found that spontaneous pneumomediastinum is an uncommon presentation of severe coronavirus disease 2019 (COVID-19) patients. The mechanisms of pneumomediastinum remain unclear [2] . From March 2020 to November 2020 we identified eight patients with pneumomediastinum at intensive care unit admission among 401 COVID-19 patients in two Seine-Saint-Denis hospitals in the Paris (France) area. Neither risk factor nor underlying respiratory disease was identified in these patients. Spontaneous pneumomediastinum occurred without mechanical ventilation (neither noninvasive nor invasive) for four patients and on the day following tracheal intubation despite lung-protective invasive ventilation for the others. Tracheal and bronchial integrity was verified by direct bronchoscopic examination and high-resolution chest computed tomography. As reported by LEMMERS et al. [1] , plateau pressure was constantly <25 cmH 2 O in the four patients under invasive mechanical ventilation, suggesting that pneumomediastinum were not related to barotrauma or traumatic tracheal intubation.

A similar observation was made in patients with severe acute respiratory syndrome in 2003 [3] , but no physiopathological mechanism was identified. We here propose a hypothesis to explain pneumomediastinum in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Some patients with severe COVID-19 present extensive ground-glass opacities which contribute to hypoxaemia, but also reflect the intense inflammatory process occurring in the lung (figure 1). The inflammation can generate a retractive process illustrated by the bronchiectasis and the pneumomediastinum. Such a phenomenon is also seen in acute exacerbation of idiopathic pulmonary fibrosis [4] , pleuroparenchymal fibroelastosis or melanoma-differentiation-associated protein 5 related interstitial lung diseases [5] . The high speed of inflammation installation and lung architectural change in these conditions could possibly explain the onset of pneumomediastinum.

In COVID-19 patients with pneumomediastinum, we believe that physicians should consider initiation of anti-inflammatory treatment to stop retractive processes and should not refrain from using steroids for SARS-CoV-2 pneumonia. @ERSpublications Pneumomediastinum in severe #COVID19 presentations could be due to a lung parenchymal retractive process generated by intense inflammation as in acute exacerbation of idiopathic pulmonary fibrosis or MDA-5 acute interstitial lung disease https://bit.ly/3qzBYMW

Pneumomediastinum and subcutaneous emphysema in COVID-19: barotrauma or lung frailty?

COVID-19 with spontaneous pneumomediastinum

Spontaneous pneumomediastinum in patients with severe acute respiratory syndrome

Spontaneous pneumomediastinum as a potential predictor of mortality in patients with idiopathic pulmonary fibrosis

Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis

FIGURE 1 Ground-glass opacities in severe coronavirus disease 2019 reflect the intense inflammatory process occurring in the lung. The inflammation can generate a retractive process illustrated by the bronchiectasis (white arrow) and the pneumomediastinum